R-Tech Ueno, Ltd. engages in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment of ophthalmology and dermatology worldwide. The company offers Rescula eye drops to treat glaucoma and ocular hypertension. Its product pipeline comprises UF-021, which is in Phase IIb clinical trials to treat retinitis pigmentosa; RU-101 which is in Phase IIa clinical trials for the treatment of dry eye; and RK-023 that is in Phase IIa clinical trials to treat alopecia. The company is also developing RTU-1096 for the treatment of diabetes macular edema and diabetic neuropathy; and RTU-009 for treating acute cerebral infarction and graft-versus-host diseases. In addition, it engages in contract manufacturing of injections, eye drops, liquid drugs, liquid-filled hard capsules, solid formulations, and ointments. R-Tech Ueno, Ltd. was founded in 1989 and is headquartered in Tokyo, Japan. As of October 13, 2015, R-Tech Ueno, Ltd. operates as a subsidiary of Sucampo Pharma, LLC.
r-tech ueno ltd (4573:Tokyo)
NBF Hibiya Builing
Phone: 81 3 3596 8011
Fax: 81 3 3596 8023www.rtechueno.com
|No competitor information is available for 4573.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact R-TECH UENO LTD, please visit www.rtechueno.com. Company data is provided by Capital IQ. Please use this form to report any data issues.